Abstract Body

Background

Uganda’s drive toward triple elimination of mother-to-child transmission of HIV, syphilis, and hepatitis B demands screening tools that are accurate, rapid, and affordable. Triple rapid diagnostic tests (RDTs) that simultaneously detect HIV antigen/antibody, treponemal antibodies, and hepatitis B surface antigen (HBsAg) provide a consolidated approach suitable for antenatal and routine laboratory screening. Currently, testing coverage among pregnant and breastfeeding women is high for HIV (96%) and syphilis (94%) but lags for hepatitis B (67%), largely because services rely on dual HIV/syphilis RDTs alongside single-analyte HBsAg tests. To inform policy and optimize workflow, we conducted a laboratory-only pre-evaluation of a triple RDT to assess diagnostic performance, usability, and programmatic fit.

Methods

At the Central Public Health Laboratories (CPHL), 300 archived plasma specimens were tested. A 50 HIV-reactive, 50 treponemal-reactive, 50 HBsAg-reactive, and 150 non-reactive. Reference standards were enzyme immunoassay (EIA) for HIV, TPPA/TPHA for syphilis, and chemiluminescent immunoassay (CLIA) for HBsAg. Outcomes included sensitivity, specificity (95% CIs), overall agreement, Cohen’s κ, invalid rate, and inter-operator reproducibility.

Results

The triple RDT showed excellent agreement with reference assays. For HIV, sensitivity and specificity were both 100% (95% CI: 92.9–100 and 98.5–100, respectively; κ = 1.00). For syphilis, sensitivity was 96.0% (95% CI: 86.3–99.5) and specificity was 100% (95% CI: 98.5–100), with κ = 0.96, while for hepatitis B, both sensitivity and specificity were 100% (95% CI: 92.9–100 and 98.5–100; κ = 1.00). Inter-operator agreement exceeded 99% (κ ≥ 0.95), the invalid rate was 1.3% (4/300, with most resolving on repeat), and usability assessments showed a hands-on time of approximately 5 minutes with results available in 15–20 minutes.

Conclusions

The results demonstrated excellent diagnostic accuracy for HIV and HBsAg and high performance for syphilis, with strong reproducibility, few invalids, and straightforward usability. These results support integrating triple RDTs into Uganda’s laboratory testing for pregnant and breastfeeding women to close current coverage gaps, particularly for hepatitis B, while sustaining high HIV and syphilis screening performance.